home

Disparity in
Schizophrenic
Treatment

We develop biology-driven medicines for neuropsychiatric conditions so that patients can get better faster.

Unmet need of Schizophrenia

Schizophrenia is a psychiatric disorder that affects about 1% of the
world population (more than 2.4 million individuals in US) with long-
lasting behavioral consequences The disease is manifested by a set
of abnormal behaviors including psychosis, social withdrawal, and cognitive deficits. These behavioral modifications are accompanied
by specific changes in brain structures, neurotransmission and
synaptic signaling. Despite more than 50 years of research, the underlying causes are not well understood and there is no cure.

Current medications (with annual global sales of $20 billion) are not effective in treating major symptoms such as cognitive deficits which
produce serious debilitating site effects such that about 75% of
patents become noncompliant after 18 months of treatment

Our Technology

Through research and development has discovered a unique brain signaling mechanism that plays a vital role in regulation of cognition and memory. The company has unique pharmacological tools to regulate the function of these signaling mechanisms to benefit and correct cognitive malfunctions present in a range of CNS diseases.